Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Chawla, Sant P ^a   Staddon, Arthur ^b   Hendifar, Andrew ^a   Messam, Conrad A ^c   Patwardhan, Rita ^c   Kamel, Yasser Mostafa ^d  

^a Sarcoma Oncology Center   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Chemotherapy; Chemotherapy induced thrombocytopenia; Myelosuppression; Platelets; Sarcoma; Thrombopoietin receptor agonists

Indexed keywords

DOXORUBICIN; ELTROMBOPAG; IFOSFAMIDE; MESNA; RAZOXANE;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; DEHYDRATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART PALPITATION; HEMATEMESIS; HEMATURIA; HEMOPTYSIS; HEMORRHOID; HUMAN; HYPERVITAMINOSIS; HYPOCALCEMIA; HYPOKALEMIA; LEUKOPENIA; LUNG EMBOLISM; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPTIMAL BIOLOGICAL DOSE; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PROTEINURIA; SEPSIS; SIDE EFFECT; SOFT TISSUE SARCOMA; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT OUTCOME; VEIN THROMBOSIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; HYDRAZINES; IFOSFAMIDE; MALE; MIDDLE AGED; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; SARCOMA; SOFT TISSUE NEOPLASMS; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84874930762     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-121     Document Type: Article

References (24)

1. Ang JE, Shah RN, Everard M, Keyzor C, Coombes I, Jenkins A, Thomas K, A'Hern R, Jones RL, Blake P, et al. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. Ann Oncol 2009, 20(11):1787-1793. 10.1093/annonc/mdp193, 19542250.
2. Blay JY, von Mehren M, Samuels BL, Fanucchi MP, Ray-Coquard I, Buckley B, Gilles L, Lebedinsky C, Elsayed YA, Le Cesne A. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 2008, 14(20):6656-6662. 10.1158/1078-0432.CCR-08-0336, 2777645, 18927308.
3. Hensley ML, Sill MW, Scribner DR, Brown J, Debernardo RL, Hartenbach EM, McCourt CK, Bosscher JR, Gehrig PA. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a gynecologic oncology group phase II study. Gynecol Oncol 2009, 115(3):460-465. 10.1016/j.ygyno.2009.09.011, 2783261, 19811811.
4. Kantarjian H, Coutre PL, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 2010, 116(11):2665-2672. 2876208, 20310049.
5. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 2005, 10(10):833-841. 10.1634/theoncologist.10-10-833, 16314294.
6. Worden FP, Taylor JM, Biermann JS, Sondak VK, Leu KM, Chugh R, McGinn CJ, Zalupski MM, Baker LH. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005, 23(1):105-112.
7. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist 2007, 12(11):1351-1360. 10.1634/theoncologist.12-11-1351, 18055856.
8. Lashkari A, Chow WA, Valdes F, Leong L, Phan V, Twardowski P, Kapoor N, Molina A, Al-Kadhimi Z, Frankel P, et al. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res 2009, 29(8):3281-3288.
9. Maurel J, Lopez-Pousa A, de Las PR, Fra J, Martin J, Cruz J, Casado A, Poveda A, Martinez-Trufero J, Balana C, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol 2009, 27(11):1893-1898. 10.1200/JCO.2008.19.2930, 19273704.
10. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010, 46(1):72-83. 10.1016/j.ejca.2009.09.022, 19853437.
11. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the american society of clinical oncology. J Clin Oncol 2001, 19(5):1519-1538.
12. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol 2009, 46(1 Suppl 2):S26-32.
13. Gordon MS, McCaskill-Stevens WJ, Battiato LA, Loewy J, Loesch D, Breeden E, Hoffman R, Beach KJ, Kuca B, Kaye J, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996, 87(9):3615-3624.
14. Brown JR, Demetri GD. Challenges in the development of platelet growth factors: low expectations for low counts. Curr Hematol Rep 2002, 1(2):110-118.
15. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357(22):2237-2247. 10.1056/NEJMoa073275, 18046028.
16. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373(9664):641-648. 10.1016/S0140-6736(09)60402-5, 19231632.
17. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011, 377(9763):393-402. 10.1016/S0140-6736(10)60959-2, 20739054.
18. Bussel JB, Psaila B, Saleh MN, Vasey S, Mayer B, Stone NL, Arning M. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. Blood 2008, 112(11). Abstract 3431 http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/3431?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=bussel&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT.
19. Saleh MN, Cheng G, Bussel JB, Sun H, Mayer B, Bailey C, Brainsky A. EXTEND study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010. Blood 2010, 116(21). Abstract 67 http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/67?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=saleh&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT.
20. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357(22):2227-2236. 10.1056/NEJMoa073255, 18046027.
21. Afdhal N, Dusheiko G, Giannini EG, Chen P-J, Han K-H, Moshin A, Rodriguez-Torres M, Rugina S, Lawitz E, Shiffman ML, et al. Final results of ENABLE 1, a phase 3, multicenter study of eltrombopag as an adjunct for antiviral treatment of hepatitis C virus-related chronic liver disease associated with thrombocytopenia. Hepatology 2011, 54(S1):100A. Abstract LB-3.
22. Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, Patwardhan R, Messam C, Mostafa Kamel Y. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin 2010, 26(10):2339-2346. 10.1185/03007995.2010.510051, 20735290.
23. Cairo MS. Dose reductions and delays: limitations of myelosuppressive chemotherapy. Oncology (Williston Park) 2000, 14(9 Suppl 8):21-31.
24. Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther 2009, 31(Pt 2):2416-2432.